Skip to main content

Ocular Surface Disease

2
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
RestasisPhase 1/21 trial
Active Trials
NCT04918823Completed10Est. Apr 2023
Biocorp
BiocorpFrance - Issoire
1 program
1
CycloSPORINE Ophthalmic 0.1% Ophthalmic EmulsionPhase 11 trial
Active Trials
NCT04812951Completed101Est. Feb 2022
Medivis
MedivisNY - Brooklyn
1 program
HydrocortisoneN/A1 trial
Active Trials
NCT04536129Completed90Est. Mar 2020
Santen
SantenCA - Emeryville
1 program
Tafluprost, timolol maleateN/A1 trial
Active Trials
NCT04828057Completed50Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieRestasis
BiocorpCycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion
SantenTafluprost, timolol maleate
MedivisHydrocortisone

Clinical Trials (4)

Total enrollment: 251 patients across 4 trials

NCT04918823AbbVieRestasis

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

Start: Jul 2021Est. completion: Apr 202310 patients
Phase 1/2Completed
NCT04812951BiocorpCycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery

Start: Feb 2021Est. completion: Feb 2022101 patients
Phase 1Completed
NCT04828057SantenTafluprost, timolol maleate

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Start: Sep 2021Est. completion: Aug 202250 patients
N/ACompleted
NCT04536129MedivisHydrocortisone

Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure

Start: Nov 2019Est. completion: Mar 202090 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.